Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

11

Portfolio Exits

4

About Henri Termeer

Henri Termeer Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Henri Termeer News

The Termeer Foundation Announces Recipients of 2022 Henri Termeer Fellowship

Apr 26, 2022

Recent Class of Emerging Life Science Entrepreneurs and First-time CEOs Cited for Initial Success as Biotech Leaders and Potential for Future Success April 26, 2022 09:19 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )--The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced that the Class of 2022 Henri Termeer Fellows has been named; the latest to receive this honor within the Fellowship program which began in 2018. The Henri Termeer Fellowship is awarded annually to emerging leaders within the life science industry who have shown initial promise as company founders, CEOs or heads of life science organizations and are dedicated to developing life-changing treatments for patients. Fellows receive membership in The Henri Termeer Network, a select group of emerging and established healthcare leaders who provide access to their collective and valuable industry experience to help all Termeer Fellows advance their businesses and scientific programs. Additional Fellowship benefits include mentorship, network building and professional development as well as peer-to-peer learning, and access to other events and initiatives sponsored by The Termeer Foundation. “This year’s group of Termeer Fellows represents a tremendous group of scientists and business leaders involved in novel work with strong potential impact on medical research, the business of biotech and ultimately those patients who live with a host of unmet medical needs,” said Belinda Termeer, President of The Termeer Foundation. “It is the Foundation’s goal, through this recognition, to accelerate each Fellow’s visionary work and future developments, so that they may continue their innovative and insightful work across a diverse set of scientific platforms.” The 2022 Fellows include: Alex Federation, Talus Bioscience, Inc., Daniel Fischer, Tevard Biosciences, Elizabeth Wood, JURA Bio, Inc., Xavier Duportet, Eligo Bioscience, Yael Weiss, Mahzi Therapeutics, Laura Kleiman, Reboot Rx, Lukas Lange, Probably Genetic, and Claudine van der Sande, Xinvento. More on the Class of 2022 Fellows can be found here . “Each year the selection of the Termeer Fellows becomes increasingly more competitive and challenging, and this year’s pool of outstanding applicants all have incredible promise of making a meaningful difference in the life science industry,” said Alan Walts, Co-Founder and Member of the Board of Directors, The Termeer Foundation. “The depth and range of each applicant’s background demonstrates the need for novel biomedical research and underscores the potential value for improving the health for patients.” About The Termeer Foundation Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation . Contacts

Henri Termeer Investments

11 Investments

Henri Termeer has made 11 investments. Their latest investment was in Arrakis Therapeutics as part of their Series B on April 4, 2019.

CBI Logo

Henri Termeer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/18/2019

Series B

Arrakis Therapeutics

$75M

No

7

12/21/2017

Series C

Aura Biosciences

$30M

No

10

2/27/2017

Series A

Arrakis Therapeutics

$38M

Yes

5

9/29/2016

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

8/22/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/18/2019

12/21/2017

2/27/2017

9/29/2016

8/22/2016

Round

Series B

Series C

Series A

Series B - II

Series A

Company

Arrakis Therapeutics

Aura Biosciences

Arrakis Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$75M

$30M

$38M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

10

5

10

10

Henri Termeer Portfolio Exits

4 Portfolio Exits

Henri Termeer has 4 portfolio exits. Their latest portfolio exit was Amylyx Pharmaceuticals on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

6

10/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/13/2018

Acquired

Subscribe to see more

Subscribe to see more

10

6/26/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

10/29/2021

2/13/2018

6/26/2013

Exit

IPO

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.